Stockscreener 앱 받기
6.45
4.44%
-0.30
시간 외 거래:
6.44
-0.010
-0.16%
Cartesian Therapeutics Inc 주식(RNAC)의 최신 뉴스
Cartesian Therapeutics secures up to $150 million financing - The Pharma Letter
RNAC Maintained by Needham -- Price Target Lowered to $40.00 - GuruFocus
Cartesian Therapeutics stock price target maintained at $40 by Mizuho - Investing.com Canada
Cartesian Therapeutics secures $150M non-dilutive financing, advancing CAR-T trials with key data expected in 2027. - Pluang
Cartesian Therapeutics Secures $150 Million Loan Agreement with K2 HealthVentures and Ankura Trust Company - Minichart
Cartesian Therapeutics (RNAC) Secures $150M Credit Facility for Growth Initiatives - GuruFocus
Cartesian Therapeutics Lands Up to $150 Million in Non-Dilutive Financing to Support CAR-T Commercialization Push - citybiz
Cartesian Therapeutics IncEnters loan and security agreement on May 22SEC filing - marketscreener.com
Cartesian Secures Major Loan Facility to Extend Runway - TipRanks
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 - The Manila Times
Milos Miljkovic to Depart Cartesian Therapeutic as Chief Medical Officer; Separation Agreement Expected - TradingView
Cartesian Therapeutics secures up to 150 million dollar credit facility to extend cash runway to 2028 - Traders Union
Cartesian Therapeutics (NASDAQ: RNAC) adds $150M credit line and extends cash runway - Stock Titan
Up to $150M backs CAR-T for myasthenia gravis, data in 2027 - Stock Titan
Cartesian Therapeutics (RNAC) Q1 2026 Earnings Miss: Breaking Down the NumbersEarnings Revision Upgrade - Newser
Cartesian Therapeutics (RNAC) Q1 2026 Earnings: Soft Quarter Raises QuestionsCollaborative Trading Signals - Newser
Cartesian Therapeutics (RNAC) Drops -7.33% — Key Support at $6.07 2026-05-19Investment Signal Network - newser.com
Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight - GlobeNewswire Inc.
Today's Analyst Ratings: Needham Reiterates Buy Rating for RNAC - GuruFocus
We're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate - Yahoo Finance
Cartesian Therapeutics, Inc. (RNAC) soars 10.3%: Is further upside left in the stock? - MSN
Q2 EPS Estimate for Cartesian Therapeutics Cut by Analyst - MarketBeat
TradingKey - TradingKey
RNAC Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Cartesian Therapeutics stock price target lowered to $25 by H.C. Wainwright on launch timing - Investing.com Canada
Cartesian Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference - Quiver Quantitative
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - The Manila Times
Number of shareholders of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
Cell therapy advances for myasthenia gravis presented by Cartesian Therapeutics at major conference - Traders Union
RNAC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
TD Cowen Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating - Moomoo
Insider Sales At Cartesian Therapeutics Landed A Good Price - Moomoo
CARTESIAN THERAPEUTICS, INC. (RNAC) - MSN
FMR LLC (RNAC) holds 799,743 shares, 3.0% stake — Amendment No. 4 - Stock Titan
Cartesian Therapeutics Inc (RNAC) - MSN
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
Five new Cartesian hires get stock options priced at $6.22 - Stock Titan
The labor dynamics in Cartesian Therapeutics (RNAC) results | Cartesian Therapeutics Posts Steep 62% EPS MissExpert Market Insights - newser.com
Cartesian Therapeutics, Inc. (RNAC) reports Q1 loss, lags revenue estimates - MSN
RNAC Reiterated by Cartesian Therapeutics -- Price Target Mainta - GuruFocus
Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics Reports Q1 2026 Financial Results and Advances Descartes-08 Clinical Trials in Autoimmune Diseases - Minichart
Cartesian Therapeutics (NASDAQ:RNAC) Posts Quarterly Earnings Results - MarketBeat
Cartesian Therapeutics, Inc. Q1 2026 Financial Report: Forward-Looking Statements, Risks, and Financial Results - Minichart
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Cartesian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Myasthenia Gravis Market: Fast-Growing Therapeutics Outlook by 2034 – DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - Barchart.com
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Cartesian Therapeutics posts first quarter 2026 financial results and issues business update - Traders Union
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
8-K: Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updatemoomoo - Moomoo
Cartesian Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Cartesian Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
0.98%
0.12%
자본화:
|
볼륨(24시간):